Group items tagged

International Academy for Clinical Hematology 7th Annual Meeting is organized by CME Congresses Ltd and will be held from Sep 19 - 21, 2024 in Paris. The program will provide a platform to interact and discuss with leading experts many key and developing issues in clinical hematology and within these specialized fields.

The microfluidics market is valued at 8.28 Billion in 2017 and is expected to grow at a CAGR of 22.6% during the forecast period, to reach to USD 27.91 Billion by 2023. Base year considered for the report is 2017 and the forecast period includes 2018 to 2023. The increasing incidence of other major chronic and infectious diseases, coupled with advancements in coagulation tests, blood gas electrolytes, hematology, urine chemistry, and cardiac markers, are creating new avenues for the growth of the POC diagnostics market. This, in turn, is expected to support the growth of the microfluidics market as POC testing is the largest segment of the microfluidics market for in vitro diagnostics.

The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a trial presented at the American Society of Hematology meeting in San Diego. Darzalex, a monoclonal antibody that targets a protein found on the surface of myeloma cells known as CD38, significantly reduced patients' risk of developing the blood cancer and improved their survival in an international late-stage trial. "These results are a major advancement in the treatment of high-risk smoldering multiple myeloma," study leader Dr. S. Vincent Rajkumar of the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota said in a statement. In smoldering multiple myeloma, abnormal plasma cells accumulate in the bone marrow. As the abnormal cells and certain proteins accumulate, a patient's risk for cancer increases.